Lexeo Therapeutics (LXEO) Institutional Ownership $6.28 +0.24 (+3.97%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Lexeo Therapeutics (NASDAQ:LXEO)CurrentInstitutional OwnershipPercentage60.67%Number ofInstitutional Buyers(last 12 months)28TotalInstitutional Inflows(last 12 months)$129.88MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$26.76M Get LXEO Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexeo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LXEO Institutional Buying and Selling by Quarter Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Lexeo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails12/13/2024 Exome Asset Management LLC88,148$797K0.5%N/A0.267% 11/19/2024 Barclays PLC50,210$454K0.0%+162.2%0.152% 11/16/2024 Geode Capital Management LLC553,247$5.00M0.0%+86.5%1.673% 11/15/2024 Frazier Life Sciences Management L.P.1,250,786$11.31M0.5%N/A3.783% 11/15/2024 Barclays PLC50,210$454K0.0%+162.2%0.152% 11/15/2024 Jane Street Group LLC35,677$323K0.0%+33.3%0.108% Get the Latest News and Ratings for LXEO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 Wellington Management Group LLP51,892$469K0.0%+134.8%0.157% 11/15/2024 State Street Corp253,946$2.30M0.0%+29.4%0.768% 11/15/2024 RA Capital Management L.P.546,554$4.94M0.1%-18.8%1.653% 11/15/2024 Point72 Asset Management L.P.370,407$3.35M0.0%N/A1.120% 11/15/2024 Polar Asset Management Partners Inc.59,800$541K0.0%-8.4%0.181% 11/15/2024 Ikarian Capital LLC257,216$2.33M0.3%N/A0.778% 11/15/2024 Jacobs Levy Equity Management Inc.30,346$274K0.0%N/A0.092% 11/15/2024 Janus Henderson Group PLC3,763,195$34.00M0.0%+18.9%11.383% 11/14/2024 PDT Partners LLC26,608$241K0.0%N/A0.080% 11/14/2024 Braidwell LP728,777$6.59M0.2%-47.3%2.204% 11/14/2024 Eventide Asset Management LLC1,855,986$16.78M0.3%-44.9%5.614% 11/14/2024 Verition Fund Management LLC777,320$7.03M0.0%+84.5%2.351% 11/14/2024 Vestal Point Capital LP850,000$7.68M0.6%+1.2%2.571% 11/14/2024 MetLife Investment Management LLC14,223$129K0.0%+121.5%0.043% 11/13/2024 BNP Paribas Financial Markets5,541$50K0.0%+184.2%0.017% 11/12/2024 Charles Schwab Investment Management Inc.63,874$577K0.0%+107.0%0.193% 10/24/2024 Novo Holdings A S1,122,581$10.15M0.5%-22.6%3.407% 10/23/2024 Values First Advisors Inc.7,446$67K0.0%N/A0.023% 8/20/2024 Novo Holdings A S1,450,500$23.27M1.2%-11.5%4.403% 8/1/2024 Rhumbline Advisers13,357$214K0.0%+37.3%0.041% 7/26/2024 Bank of New York Mellon Corp31,806$510K0.0%+12.3%0.097% 5/17/2024 RA Capital Management L.P.660,938$10.36M0.1%N/A2.006% 5/17/2024 Artal Group S.A.801,716$12.57M0.3%+32.9%2.434% 5/16/2024 Janus Henderson Group PLC2,540,785$39.80M0.0%+9.0%7.713% 5/14/2024 American International Group Inc.5,053$79K0.0%N/A0.015% 5/10/2024 Vanguard Group Inc.481,755$7.55M0.0%+15.8%1.462% 5/1/2024 BNP Paribas Financial Markets4,781$75K0.0%N/A0.015% 4/29/2024 Cornell University126,258$1.98M30.0%N/A0.383% 2/20/2024 Eventide Asset Management LLC3,002,831$40.30M0.7%N/A11.268% 2/15/2024 Omega Fund Management LLC2,157,623$28.96M23.5%N/A8.096% 2/15/2024 Blackstone Inc.696,110$9.34M0.0%N/A2.612% (Data available from 1/1/2016 forward) LXEO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LXEO shares? During the previous two years, 31 institutional investors and hedge funds held shares of Lexeo Therapeutics. The most heavily invested institutionals were Janus Henderson Group PLC ($34.00M), Omega Fund Management LLC ($28.96M), Eventide Asset Management LLC ($16.78M), Artal Group S.A. ($12.57M), Frazier Life Sciences Management L.P. ($11.31M), Novo Holdings A S ($10.15M), and Blackstone Inc. ($9.34M).Learn more on LXEO's institutional investors. What percentage of Lexeo Therapeutics stock is owned by institutional investors? 60.67% of Lexeo Therapeutics stock is owned by institutional investors. Learn more on LXEO's institutional investor holdings. Which institutional investors have been buying Lexeo Therapeutics stock? Of the 28 institutional investors that purchased Lexeo Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Eventide Asset Management LLC ($3.00M), Omega Fund Management LLC ($2.16M), Frazier Life Sciences Management L.P. ($1.25M), Janus Henderson Group PLC ($809.25K), Blackstone Inc. ($696.11K), RA Capital Management L.P. ($660.94K), and Point72 Asset Management L.P. ($370.41K). How much institutional buying is happening at Lexeo Therapeutics? Institutional investors have bought a total of 10,590,232 shares in the last 24 months. This purchase volume represents approximately $129.88M in transactions. Which Lexeo Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Lexeo Therapeutics stock in the last 24 months: Eventide Asset Management LLC ($1.51M), Braidwell LP ($653.70K), Novo Holdings A S ($515.72K), RA Capital Management L.P. ($126.16K), and Polar Asset Management Partners Inc. ($5.50K). How much institutional selling is happening at Lexeo Therapeutics? Institutional investors have sold a total of 2,814,240 shares in the last 24 months. This volume of shares sold represents approximately $26.76M in transactions. Related Companies Phibro Animal Health Institutional Ownership Cogent Biosciences Institutional Ownership Nuvation Bio Institutional Ownership ArriVent BioPharma Institutional Ownership Immatics Institutional Ownership uniQure Institutional Ownership Replimune Group Institutional Ownership 89bio Institutional Ownership Pliant Therapeutics Institutional Ownership Relay Therapeutics Institutional Ownership This page (NASDAQ:LXEO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
